Trial · NCT07912294
Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction
NCT07912294, Not applicable, Not yet recruiting, King Abdulaziz University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction. Trials, record NCT07912294. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912294
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Calcium Hydroxylapatite and Hyaluronic Acid for Interdental Papilla Reconstruction
- NCT number
- NCT07912294
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- King Abdulaziz University
- Conditions
- Loss of Interdental Papillae, Black Triangles Syndrome (BTS)
- Interventions
- Calcium Hydroxylapatite (CaHA) Injectable Filler., Hyaluronic Acid (HA) Injectable Filler
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction in Black Triangle Area | Baseline, 3 weeks, 3 months, and 6 months after treatment. | Change in the area of the open gingival embrasure (black triangle) following treatment, measured in square millimeters (mm²) using standardized calibrated digital clinical photographs. The reduction in black triangle area will be compared between the calcium hydroxylapatite and hyaluronic acid treatment sites to evaluate the effectiveness of papillary reconstruction. |
| Primary | Change in Interdental Papilla Height | Baseline, 3 weeks, 3 months, and 6 months after treatment. | Change in interdental papilla height (mm) from baseline following treatment with hyper-diluted calcium hydroxylapatite or hyaluronic acid. Papillary height will be measured using standardized digital clinical photographs calibrated with a UNC-15 periodontal probe and analyzed using image-analysis software (ImageJ). The distance from the papilla tip to a reference line connecting the adjacent gingival margins will be measured. Changes in papillary height will be compared between the two treatment sites. |
| Secondary | Change in Interdental Papilla Thickness | Baseline, 3 weeks, 3 months, and 6 months after treatment. | Change in interdental papilla thickness (mm) following treatment with calcium hydroxylapatite or hyaluronic acid. Tissue thickness will be assessed using a calibrated endodontic file fitted with a silicone stopper at a standardized reference point. Changes in tissue thickness will be compared between treatment sites to estimate improvements in papillary tissue bulk. |
| Secondary | Patient Satisfaction With Esthetic Outcomes | 3 weeks, 3 months, and 6 months after treatment. | Patient satisfaction with the appearance of the treated interdental papilla will be assessed using a Visual Analog Scale (VAS). Participants will evaluate their satisfaction with the esthetic improvement achieved following each treatment. Satisfaction scores will be compared between the two treatment sites. |
| Secondary | Global Aesthetic Improvement Scale (GAIS) | 3 weeks, 3 months, and 6 months after treatment. | Esthetic improvement will be assessed using the Global Aesthetic Improvement Scale (GAIS), a five-point scale ranging from "worse" to "very much improved." Both participants and investigators will evaluate the improvement in interdental papilla appearance compared with baseline. Scores will be compared between the two treatment sites. |
| Secondary | Stability of Interdental Papillary Fill | 3 weeks, 3 months, and 6 months after treatment. | The stability of interdental papillary reconstruction will be evaluated by comparing changes in papilla height and black triangle dimensions across follow-up visits. The maintenance of treatment-related improvements at 6 months will be assessed to compare the durability of calcium hydroxylapatite and hyaluronic acid injections. |
| Other | Patient Satisfaction Questionnaire (PSQ-18) | 3 weeks, 3 months, and 6 months after treatment. | Patient-reported satisfaction will be evaluated using the Patient Satisfaction Questionnaire Short Form (PSQ-18), consisting of 18 items. The questionnaire will assess satisfaction with treatment, comfort, perceived improvement, and overall treatment experience. Responses will be compared between the two treatment sites. |
| Other | Adverse Events and Complications | From the injection procedure through the 6-month follow-up period. | Any adverse effects or complications associated with calcium hydroxylapatite or hyaluronic acid injections will be recorded and compared between the treatment sites. The number and nature of reported complications will be documented to evaluate the safety of both interventions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912294
GET https://conductscience.org/api/trials/v1/NCT07912294/registered